前收市價 | 14.66 |
開市 | 14.63 |
買盤 | 14.08 x 400 |
賣出價 | 14.17 x 400 |
今日波幅 | 13.84 - 14.81 |
52 週波幅 | 6.81 - 29.70 |
成交量 | |
平均成交量 | 252,180 |
市值 | 293.474M |
Beta 值 (5 年,每月) | 0.87 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -11.60 |
業績公佈日 | 2024年5月09日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 40.00 |
The heavy selling pressure might have exhausted for Adverum Biotechnologies (ADVM) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Here is how Adverum Biotechnologies (ADVM) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
There are plenty of penny stocks ready to pop. However, we have to remember that penny stocks are extremely risky, and can be costly in the end. So, one, never risk more than you can afford to lose on any penny stock. That’s even if you believe it’s a “sure thing.” Two, don’t just buy any penny stock out there. Make sure you do your due diligence. Three, take some advice from the SEC. “Penny stocks may trade infrequently — which means that it may be difficult to sell penny stock shares once you